Hans de Haard

5.0k total citations
79 papers, 3.3k citations indexed

About

Hans de Haard is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, Hans de Haard has authored 79 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Radiology, Nuclear Medicine and Imaging, 35 papers in Molecular Biology and 35 papers in Immunology. Recurrent topics in Hans de Haard's work include Monoclonal and Polyclonal Antibodies Research (50 papers), Glycosylation and Glycoproteins Research (21 papers) and T-cell and B-cell Immunology (13 papers). Hans de Haard is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (50 papers), Glycosylation and Glycoproteins Research (21 papers) and T-cell and B-cell Immunology (13 papers). Hans de Haard collaborates with scholars based in Belgium, Netherlands and France. Hans de Haard's co-authors include Torsten Dreier, Theo Verrips, Christophe Blanchetot, Michael Saunders, Els Beirnaert, Marc Lauwereys, Bas van der Woning, Marie Godar, Peter Ulrichts and E. Sally Ward and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Hans de Haard

77 papers receiving 3.2k citations

Peers

Countries citing papers authored by Hans de Haard

Since Specialization

Citations

This map shows the geographic impact of Hans de Haard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans de Haard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans de Haard more than expected).

Fields of papers citing papers by Hans de Haard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans de Haard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans de Haard. The network helps show where Hans de Haard may publish in the future.

Co-authorship network of co-authors of Hans de Haard

This figure shows the co-authorship network connecting the top 25 collaborators of Hans de Haard. A scholar is included among the top collaborators of Hans de Haard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans de Haard. Hans de Haard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models 2023 ·EJNMMI Radiopharmacy and Chemistry ·(unknown), Tal Flieswasser, (unknown), Christel Vangestel, Alan Miranda, Hans de Haard, Julie Jacobs, Evelien Smits, Tim Van den Wyngaert, Filipe Elvas	17
2	The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement 2022 ·Nature Communications ·Maximilian Brinkhaus, (unknown), (unknown), Arthur E. H. Bentlage, Ninotska I. L. Derksen, (unknown), Bianca Balbino, Magdalena Sips, Peter Ulrichts, Peter Verheesen, Hans de Haard, Theo Rispens, Savvas N. Savvides, Gestur Vidarsson	27
3	The CD70-CD27 axis in oncology: the new kids on the block 2022 ·Journal of Experimental & Clinical Cancer Research ·Tal Flieswasser, (unknown), Jonas R.M. Van Audenaerde, Jorrit De Waele, Filip Lardon, Carsten Riether, Hans de Haard, Evelien Smits, Patrick Pauwels, Julie Jacobs	109
4	Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer 2020 ·Nature Communications ·(unknown), (unknown), (unknown), Stéphanie Liénart, Orian Bricard, (unknown), (unknown), (unknown), Gitte De Boeck, (unknown), Inge Van de Walle, Bas van der Woning, Michael Saunders, Hans de Haard, (unknown), Wim Maes, Hans Deckmyn, Pierre G. Coulie, Nicolas van Baren, Sophie Lucas	104
5	Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function 2020 ·The Journal of Immunology ·Maximilian Brinkhaus, (unknown), Arthur E. H. Bentlage, (unknown), Steven W. de Taeye, (unknown), Jacoline Gerritsen, Juk Yee Mok, Giso Brasser, Peter C. Ligthart, Wim J.E. van Esch, Peter Verheesen, Hans de Haard, Theo Rispens, Gestur Vidarsson	11
6	Protein crystallization promotes type 2 immunity and is reversible by antibody treatment 2019 ·Science ·Emma K. Persson, Kenneth Verstraete, Ines Heyndrickx, Elien Gevaert, Helena Aegerter, (unknown), Kim Deswarte, Koen H. G. Verschueren, Ann Dansercoer, Delphine Gras, Pascal Chanez, Claus Bachert, Amanda Gonçalves, Hanne Van Gorp, Hans de Haard, Christophe Blanchetot, Michael Saunders, Hamida Hammad, Savvas N. Savvides, Bart N. Lambrecht	207
7	CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry 2018 ·Biochemical Pharmacology ·(unknown), A. Klarenbeek, Vladimir Bobkov, Jordi Doijen, Marta Arimont, Chunxia Zhao, Raimond Heukers, (unknown), Chris de Graaf, Theo Verrips, Bas van der Woning, Hans de Haard, Joseph Rucker, Kurt Vermeire, Tracy M. Handel, Tom Van Loy, Martine J. Smit, Dominique Schols	43
8	Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans 2018 ·Journal of Clinical Investigation ·Peter Ulrichts, Antonio Guglietta, Torsten Dreier, (unknown), Valérie Hanssens, Erik Hofman, (unknown), Peter Verheesen, (unknown), (unknown), F. Javier Enriquez, (unknown), Raimund J. Ober, E. Sally Ward, Hans de Haard, Nicolas Leupin	251
9	Display Technologies for Generation of Ig Single Variable Domains 2018 ·Methods in molecular biology ·Vladimir Bobkov, Bas van der Woning, Hans de Haard	8
10	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies 2017 ·Clinical Cancer Research ·Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean‐Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean‐Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada	47
11	Blocking CD70/CD27 Signaling in Combination with Hypomethylating Agents Eradicates Human CD34+ AML Stem and Progenitor Cells in Vitro and In Vivo 2017 ·Blood ·Magdalena Hinterbrandner, (unknown), (unknown), Thomas Pabst, Luc Van Rompaey, Nicolas Leupin, Hans de Haard, Adrian F. Ochsenbein, Carsten Riether	5
12	Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine–Nanobody Complex 2017 ·Frontiers in Immunology ·Aline Desmyter, Silvia Spinelli, Carlo Boutton, Michael Saunders, (unknown), Hans de Haard, Geertrui Denecker, Maarten Van Roy, Christian Cambillau, Heidi Rommelaere	37
13	Neutralizing Nanobodies Targeting Diverse Chemokines Effectively Inhibit Chemokine Function 2013 ·Journal of Biological Chemistry ·Christophe Blanchetot, Dennis Verzijl, (unknown), Leontien Bosch, (unknown), Rob Leurs, C. Theo Verrips, Michael Saunders, Hans de Haard, Martine J. Smit	46
14	Improvement of Proteolytic Stability Through In Silico Engineering 2012 ·Methods in molecular biology ·Lucy Rutten, Hans de Haard, Theo Verrips	1
15	Selection of VHHs Under Application Conditions 2012 ·Methods in molecular biology ·Edward Dolk, Theo Verrips, Hans de Haard	2
16	Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides 2011 ·AIDS Research and Human Retroviruses ·Andrea Gorlani, Joachim Brouwers, Christopher McConville, Pieter van der Bijl, Karl Malcolm, Patrick Augustijns, (unknown), Robin A. Weiss, Hans de Haard, Theo Verrips	26
17	Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction 2010 ·PLoS ONE ·Andreas Hinz, D. Lutje Hulsik, Anna Forsman, (unknown), Hassan Belrhali, Andrea Gorlani, Hans de Haard, Robin A. Weiss, Theo Verrips, Winfríed Weissenhorn	30
18	Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope 2007 ·Molecular Immunology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Stefan Loverix, Els Beirnaert, Hans de Haard, Jean-Claude Schmit, Ignace Lasters	10
19	Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display 2005 ·European Journal of Human Genetics ·Yanchao Huang, Peter Verheesen, Andreas Roussis, (unknown), Ieke B. Ginjaar, Faye Haldane, Steve Laval, Louise V.B. Anderson, Theo Verrips, Rune R. Frants, Hans de Haard, Kate Bushby, Johan T. den Dunnen, Silvère M. van der Maarel	52
20	Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy 2003 ·Journal of Immunological Methods ·Silvana van Koningsbruggen, Hans de Haard, Peggy de Kievit, R.W. Dirks, Alexandra van Remoortere, Arjan J. Groot, Baziel G.M. van Engelen, Johan T. den Dunnen, C. Theo Verrips, Rune R. Frants, Silvère M. van der Maarel	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact